2.2. 2023, Experimentální hypertenze

Laboratory name: Experimental Hypertension

Laboratory website

PhD project: Gliflozins in the treatment of non-diabetic models of hypertension and heart failure

The new class of antidiabetic drugs, gliflozins (inhibitors of sodium-glucose transporter 2 – SGLT-2), exert their hypoglycaemic effects through the inhibition of the sodium-glucose transporter at renal proximal tubule promoting glucose and sodium excretion. This leads not only to a significant improvement in the control of blood glucose but also promotes the lowering of blood pressure and body weight both in diabetic patients and in experimental diabetic models. There are numerous experimental data on the effects of different gliflozins (empagliflozin, dapagliflozin, canagliflozin) in diabetic kidney and heart disease. However, the experiments in non-diabetic animals are relatively scarce. Therefore, the aim of the PhD project will be the study mechanisms of actions of these new class of antidiabetic drugs under non-diabetic conditions. 

References:

Hüttl et al: Metabolic cardio- and reno-protective effects of empagliflozin in a prediabetic rat model, J Physiol Pharmacol, 71(5), 2020

Malínská H et al: Beneficial Effects of Empagliflozin Are Mediated by Reduced Renal Inflammation and Oxidative Stress in Spontaneously Hypertensive Rats Expressing Human C-Reactive Protein. Biomedicines. 2022;10(9):2066.

Hojná S et al: Antihypertensive and metabolic effects of empagliflozin in Ren-2 transgenic rats, an experimental non-diabetic model of hypertension. Biomed Pharmacother.

2021;144:112246.

Project supervisor (email):

RNDr. Ivana Vaněčková, DSc. (Ivana.Vaneckova@fgu.cas.cz)

Candidate’s profile (requirements):

We are looking for motivated candidates with master's degree in physiology, medicine or related fields. They should be fluent in English and interested in the work with experimental animals.